Medico Remedies Limited - Asset Resilience Ratio
Medico Remedies Limited (MEDICO) has an Asset Resilience Ratio of 1.20% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medico Remedies Limited (MEDICO) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2026)
This chart shows how Medico Remedies Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MEDICO asset base.
Liquid Assets Composition Over Time
This chart breaks down Medico Remedies Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Medico Remedies Limited carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs18.44 Million | 1.2% |
| Total Liquid Assets | Rs18.44 Million | 1.20% |
Asset Resilience Insights
- Limited Liquidity: Medico Remedies Limited maintains only 1.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medico Remedies Limited Industry Peers by Asset Resilience Ratio
Compare Medico Remedies Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Medico Remedies Limited (2016–2026)
The table below shows the annual Asset Resilience Ratio data for Medico Remedies Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 1.20% | Rs18.44 Million ≈ $199.45K |
Rs1.53 Billion ≈ $16.59 Million |
-0.01pp |
| 2025-03-31 | 1.21% | Rs14.51 Million ≈ $156.88K |
Rs1.20 Billion ≈ $12.96 Million |
-0.21pp |
| 2024-03-31 | 1.42% | Rs13.63 Million ≈ $147.41K |
Rs961.95 Million ≈ $10.40 Million |
-0.03pp |
| 2023-03-31 | 1.45% | Rs12.66 Million ≈ $136.88K |
Rs874.48 Million ≈ $9.46 Million |
-0.10pp |
| 2022-03-31 | 1.55% | Rs11.79 Million ≈ $127.49K |
Rs761.90 Million ≈ $8.24 Million |
+0.15pp |
| 2021-03-31 | 1.40% | Rs10.56 Million ≈ $114.18K |
Rs756.21 Million ≈ $8.18 Million |
+0.39pp |
| 2020-03-31 | 1.01% | Rs7.60 Million ≈ $82.19K |
Rs752.69 Million ≈ $8.14 Million |
+0.42pp |
| 2019-03-31 | 0.59% | Rs4.50 Million ≈ $48.67K |
Rs763.09 Million ≈ $8.25 Million |
-0.46pp |
| 2018-03-31 | 1.05% | Rs6.22 Million ≈ $67.29K |
Rs593.85 Million ≈ $6.42 Million |
+1.02pp |
| 2017-03-31 | 0.02% | Rs120.39K ≈ $1.30K |
Rs482.46 Million ≈ $5.22 Million |
+0.36pp |
| 2016-03-31 | -0.33% | Rs-1.52 Million ≈ $-16.39K |
Rs455.43 Million ≈ $4.93 Million |
-- |
About Medico Remedies Limited
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics… Read more